Lakewood-Amedex Biotherapeutics reports preclinical safety data for Nu-3 Gel Phase 2a planning
The company said the findings support clinical dose selection for an upcoming Phase 2a trial of Nu-3 Gel, marking a development step for the program ahead of human testing.